10 Biotechnology Stocks to Buy Now

Advertisement

This week, 10 biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

This week, Stemline Therapeutics, Inc. (STML) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). For more information, get Portfolio Grader’s complete analysis of STML stock.

OncoMed Pharmaceuticals, Inc. (OMED) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. For more information, get Portfolio Grader’s complete analysis of OMED stock.

Pharmacyclics, Inc. (PCYC) gets a higher grade this week, advancing from a C last week to a B. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. For more information, get Portfolio Grader’s complete analysis of PCYC stock.

This week, Acorda Therapeutics, Inc. (ACOR) pushes up from a C to a B rating. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

Northwest Biotherapeutics, Inc. (NWBO) shows solid improvement this week. The company’s rating rises from a C to a B. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. For more information, get Portfolio Grader’s complete analysis of NWBO stock.

The rating of Prosensa Holding NV (RNA) moves up this week, rising from a B to an A. For more information, get Portfolio Grader’s complete analysis of RNA stock.

This is a strong week for MediciNova, Inc. (MNOV). The company’s rating climbs to A from the previous week’s B. Medicinova acquires, develops, and commercializes small molecule therapeutics. For more information, get Portfolio Grader’s complete analysis of MNOV stock.

This week, BioMarin Pharmaceutical’s (BMRN) ratings are up from a C last week to a B. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. For more information, get Portfolio Grader’s complete analysis of BMRN stock.

This is a strong week for Seattle Genetics, Inc. (SGEN). The company’s rating climbs to B from the previous week’s C. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. For more information, get Portfolio Grader’s complete analysis of SGEN stock.

Amgen (AMGN) boosts its rating from a B to an A this week. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. The stock’s dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2014/10/10-biotechnology-stocks-to-buy-now-stml-omed-pcyc/.

©2024 InvestorPlace Media, LLC